Clinical utility of serum chromogranin A as a marker of hepatocellular carcinoma in chronic hepatitis patients | ||||
| The Egyptian Journal of Laboratory Medicine | ||||
| Volume 32, Issue 3, August 2022 PDF (49.74 K) | ||||
| DOI: 10.4103/ejolm.ejolm_10_21 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Emad A. Awad; Tarek M. Youssef; Mohamed O. Aly; Azza A.R. Saab | ||||
| Abstract | ||||
| Background Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer deaths accounting for about 745 000 deaths per year globally. HCC is often diagnosed at an advanced stage where effective therapies are lacking. Aim Is to investigate the role of serum chromogranin A (CgA) as a marker for detection of HCC in patients with HCC complicating chronic hepatitis and correlate its serum levels with alpha fetoprotein (AFP). Results Our results revealed that there was a highly significant elevation ( < 0.01) in the median serum CgA in hepatitis-B virus -related HCC (200 ng/ml) and hepatitis-C virus-related HCC (190 ng/ml) when compared with the control group (30 ng/ml) and when compared with cirrhotic group (60 ng/ml) with no significant difference between the median serum CgA in hepatitis-B virus -related HCC and hepatitis-C virus-related HCC ( > 0.05). A highly significant positive correlation between chromogranin and AFP ( < 0.01) was found in HCC patients. On the other hand, no significant correlations were found between chromogranin and complete blood count, kidney functions, and liver-function tests in patient groups. Diagnostic reliability testing revealed that for CgA, the best cutoff for discriminating HCC patients was 100 ng/ml at which the sensitivity was 77.78%, the specificity 93.3% with positive predictive value 94.59% and negative predictive value 73.68%. Regarding the combination between CgA and AFP, it showed a sensitivity of 97.78% and a specificity of 86.67%. Conclusion Serum CgA is a promising sensitive and specific tumor marker for identification of HCC. Addition of serum CgA to the current standard tests will improve the sensitivity and accuracy of diagnosis of HCC patients and thus could allow them to benefit from earlier treatment. | ||||
| Keywords | ||||
| Chromogranin A; Hepatocellular carcinoma; Hepatitis | ||||
|
Statistics Article View: 5 PDF Download: 2 |
||||
